Is Your Child's Allowance Undermining Your Retirement?
The $1,000 Challenge, Part 9: Nibbling Away at the Family Food Bills
The Benefits of Filing Your Taxes Early
Gamblers Bet at Casinos; Investors Bet on Casinos
Aegis Capital Still Firm on SciClone Pharma (SCLN) Following Q4 Results; Zadaxin Opportunity Still Robust
SciClone Pharmaceuticals' CEO Discusses Q4 2013 Results
SciClone sees FY14 EPS 41c-47c, consensus 52c
SciClone Reports 2013 Financial Results and 2014 Outlook
SciClone reports Q4 EPS 8c, one estimate 15c
SciClone Pharmaceuticals to Report Financial Results for the Fourth Quarter and Full Year 2013 on March 12th
SciClone Appoints Charles Meng as General Counsel and Vice President of Compliance
No Impact Expected from Change in Auditor at SciClone Pharma (SCLN); China Looks Better
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of SciClone Pharmaceuticals, Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors SciClone Pharmaceuticals, Inc.